Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Revenue (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Revenue data on record, last reported at $10.6 million in Q3 2025.

  • For Q3 2025, Revenue rose 117.25% year-over-year to $10.6 million; the TTM value through Sep 2025 reached $205.6 million, up 1128.17%, while the annual FY2024 figure was $36.6 million, 316.34% up from the prior year.
  • Revenue reached $10.6 million in Q3 2025 per STOK's latest filing, down from $13.8 million in the prior quarter.
  • Across five years, Revenue topped out at $158.6 million in Q1 2025 and bottomed at $2.5 million in Q2 2023.
  • Average Revenue over 4 years is $16.4 million, with a median of $4.2 million recorded in 2024.
  • Peak YoY movement for Revenue: decreased 23.21% in 2023, then skyrocketed 3661.12% in 2025.
  • A 4-year view of Revenue shows it stood at $3.3 million in 2022, then dropped by 14.26% to $2.8 million in 2023, then soared by 707.07% to $22.6 million in 2024, then tumbled by 52.98% to $10.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $10.6 million in Q3 2025, $13.8 million in Q2 2025, and $158.6 million in Q1 2025.